肿瘤-睾丸抗原83在肿瘤中的研究进展  

Research progress of cancer-testis antigen 83 in various tumors

作　　者：肖开禺(综述) 刘新光(审校) XIAO Kaiyu;LIU Xinguang(Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics,Institute of Aging Research,Guangdong Medical University,Dongguan 523808,Guangdong Province,China)

机构地区：[1]广东医科大学衰老研究所、广东省医学免疫与分子诊断重点实验室,广东东莞523808

出　　处：《微生物学免疫学进展》2024年第5期86-91,共6页Progress In Microbiology and Immunology

基　　金：广东省基础与应用基础研究项目(地区培育项目)(2021B1515140066);东莞市社会发展科技项目(重点项目)(20211800904532)。

摘　　要：肿瘤-睾丸抗原(cancer-testis antigens,CTAs)是一类多功能蛋白,在睾丸和肿瘤细胞中特异性高表达,但在正常体细胞中不表达或低表达。这些差异表达,使其成为肿瘤标志物筛选和新型免疫疗法开发的候选靶标。肿瘤-睾丸抗原83(cancer-testis antigen 83,CT83)是CTAs的新成员,在多种癌症细胞中高表达,且与患者预后相关。目前,已开发出多种针对CT83抗原的肿瘤免疫疗法,如肿瘤疫苗、单克隆抗体、TCR-T细胞治疗。现主要就CT83在肿瘤中的研究作一概述。Cancer-testis antigens(CTAs)are a group of multifunctional proteins that are specifically highly expressed in testicular and tumor cells,but not or lowly in normal somatic cells,making these differentially expressed proteins become ideal candidate targets for the screening of tumor markers and the development of novel immunotherapies.Cancer-testis antigen 83(CT83),a new member of the CTAs group,is overexpressed in a variety of cancer cells and is associated with patient prognosis.At present,various cancer immunotherapies targeting CT83 antigen have been developed,such as tumor vaccines,monoclonal antibodies,and TCR-T cell threapies.In this paper,we review the adveince in CT38 research in tumors.

关 键 词：肿瘤相关抗原 肿瘤-睾丸抗原83 胃癌 肝癌 乳腺癌 

分 类 号：R730[医药卫生—肿瘤]